Avacopan Trial

Several US locations. Various Representatives.

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

ID number: NCT03852472

Estimated Study Completion Date  December 31, 2020

Sponsor: ChemoCentryx

Information provided by (Responsible Party): ChemoCentryx

 

Brief Summary:

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

 

A receptor inhibitor acting like a biologic and an immunosuppressant and was developed for both auto-inflammatory and autoimmune illnesses. They also have expectations that Avacopan can be used as an alternative to corticosteroids. It inhibits the complement C5a receptor, or C5aR, for inflammatory diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the for C5aR.

 

For complete details for trial see link below:

 

https://clinicaltrials.gov/ct2/show/NCT03852472

 

Please understand as soon as they fill their recruiting quota these locations will become unavailable.

 

Several US locations. You can call the number below to see if your location is participating. Or view link provided. Type in Hidradenitis Suppurativa, your area and the miles in which you are willing to travel.

 

ChemoCentryx

Contact: Jin Li    650-210-2986    jli@chemocentryx

Number 650-210-2986

 

Aurora pre-qualify link:

 

https://www.auroraforhs.com/Index.html

Get Updates

Affiliated With

  • Instagram
  • Twitter
  • Facebook Social Icon
  • Pinterest

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  Hidradenitis Suppurativa Online

PO Box 73244 Puyallup, WA 98373  |  253.256.1579